DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hematologic Neoplasms

Intervention: Piperacillin/Tazobactam (Tazocin) (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer

Official(s) and/or principal investigator(s):
Medical Monitor, MD, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer

Summary

To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.

Clinical Details

Official title: A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Hospitalized male and female patients, 18 years of age or older

- Patients who have leukemia (acute lymphocytic leukemia [ALL], acute myelogenous

leukemia [AML], chronic lymphocytic leukemia [CLL], chronic myelogenous leukemia [CML]), that is newly diagnosed, who have had initial induction, re-induction, or intensification chemotherapy or who have had a bone marrow (allogenic, syngeneic, or autologous) or peripheral blood stem-cell transplant OR Patients with lymphoma, Hodgkin's disease, multiple myeloma, myelodysplastic syndrome or myelodysplasia (refractory anemia [RA], refractory anemia with ringed sideroblasts [RARS], refractory anemia with excess blasts [RAEB], refractory anemia with excess blasts in transformation to leukemia [RAEB-T], or chronic myelomonocytic leukemia [CMML].

- Fever, defined as an oral temperature of ≥ 37. 9°C /100. 2°F, a rectal temperature ≥

38. 4°C /101. 4°F, or a tympanic temperature ≥ 38°C /100. 4°F Exclusion Criteria:

- The presence of any clinically acute or chronic disease or condition that, in the

opinion of the investigator, may interfere with the patient's ability to safely comply with the conditions of the protocol, or could preclude the evaluation of the patient's response or could make the completion of the therapy unlikely

- Neutropenia associated with syndromes that are not associated with a high risk of

bacterial infection (eg. chronic benign neutropenia or Kostmann's syndrome)

- Neutropenia due to primary bone marrow failure

Locations and Contacts

Hamilton, Canada

Montreal H1T 2M4, Canada

Ottawa K1H 8L6, Canada

Saskatoon S7N 0W8, Canada

Winnepeg R3A 1r9, Canada

Little Rock, Arkansas 72205, United States

Los Angeles, California 90089, United States

Denver, Colorado 80205, United States

Gainesville, Florida 32610, United States

North Miami, Florida 33169, United States

Ocala, Florida 34474, United States

St. Petersburg, Florida 33705, United States

Thomasville, Georgia 31792, United States

Chicago, Illinois 60611, United States

Chicago, Illinois 60637, United States

Iowa City, Iowa 52242, United States

Louisville, Kentucky 40202, United States

Camden, New Jersey 08103, United States

Hackensack, New Jersey 7601, United States

Bronx, New York 10466, United States

Buffalo, New York 14263, United States

New York, New York 10021, United States

Rochester, New York 14621, United States

Rochester, New York 14642-8668, United States

Valhalla, New York 10595, United States

Tulsa, Oklahoma 74136, United States

Philadelphia, Pennsylvania 19104, United States

Philadelphia, Pennsylvania 19107, United States

Sayre, Pennsylvania 18840, United States

Upland, Pennsylvania 19013, United States

West Reading, Pennsylvania 19611, United States

Providence, Rhode Island 02908, United States

Columbia, South Carolina 29203, United States

Houston, Texas 77030, United States

Morgantown, West Virginia 26506-9162, United States

Milwaukee, Wisconsin 53226, United States

Additional Information


Last updated: October 8, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017